Pooled analysis of clinical outcome of patients with chemorefractory metastatic colorectal cancer treated within clinical studies based on individual molecular alterations at Niguarda Cancer Center

摘要: Background: Patients with metastatic colorectal cancer (mCRC) refractory to standard therapies have poor prognosis. Rechallenge with previously used chemotherapeutics is often attempted by clinicians and considered in guidelines, but results are scanty. In this setting a reasonable approach is recruitment in clinical trials, and studies driven by selection according to individual tumor molecular characteristics are expected to provide added value.Patients and methods: We retrospectively analyzed data of patients with mCRC resistant to standard therapies treated at Niguarda Cancer Center (NCC) with chemotherapy or targeted agents in Phase I/II clinical studies based on the presence of a specific molecular profile as per inclusion criteria. Objective tumor response and progression-free survival were evaluated.Results: From June 2011 and March 2015, 1544 patients with mCRC underwent molecular screening for …